The IAP family of inhibitors of apoptosis (IAP) includes survivin. As a result of the survivin protein's ability to prevent caspase activation, apoptosis, or programmed cell death, is negatively regulated. This has been demonstrated by disruption of the pathways that induce survivin, which increases apoptosis and slows tumor growth. Only the G2-M phase of the cell cycle results in the expression of the survival protein. By interacting with tubulin during mitosis, survival localizes to the mitotic spindle and may help control the process. Antisurvivin therapy is a promising cancer treatment option because survivin is highly expressed in the majority of cancers and linked to chemotherapy resistance, increased tumor recurrence, and decreased patient survival.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V4436 | GDP366 | 501698-03-9 | GDP366 is a novel, potent, selective small molecule and dual inhibitor of survivin and Op18, it induces cell growth inhibition, cellular senescence and mitotic catastrophe in human cancer cells. |
|
V2178 | LQZ 7I | 195822-23-2 | LQZ-7I is a novel malarial protease PfSUB1 inhibitor. |
|
V0771 | YM155 (Sepantronium Bromide) | 781661-94-7 | YM155 (also called Sepantronium Bromide; YM-155; YM 155) is a novel and potent survivin inhibitor with potential anticancer activity. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
